A 32-year-old New Jersey resident, Moises A. Sanabria, recently pleaded guilty to engaging in illicit pharmaceutical transactions involving an India-based distributor and U.S. customers within a U.S. district courtroom. The guilty plea was acknowledged by the U.S. Department of Justice (DOJ), with charges for one count of conspiracy to distribute fentanyl and one count of money laundering conspiracy.
The DOJ reports finding indicate, between January 2018 and March 2021, Sanabria helped facilitate these illicit transactions, placing consumers at risk. Co-defendants Aashish K. Jain and M. Eshwar Rao, both of whom are Indian nationals, were also charged for their involvement in the conspiracy. Additionally, Jain faces charges for distributing controlled substances.
Both furanyl fentanyl and tapentadol, the controlled substances involved in the case, are intended to be prescribed by trained healthcare professionals due to their addictive properties and risk of fatal overdose. These medications require a prescription to ensure safe consumption – a requirement that was circumvented in this case as shipments came unauthorized from India.
Undercover operations placed Sanabria in custody after shipments of the controlled substances were delivered to agents from the Drug Enforcement Administration (DEA) in the southern district of Illinois. In response to the arrest, DEA official Michael E. Rehg noted that Sanabria's operation showcases an international criminal organization profiting from the dangerous misconception that pharmaceuticals may be purchased and mailed without proper documentation.
To briefly cover, their fiscal operations, Sanabria formed a limited liability company based in New York to assist with laundering and transferring roughly $114,334 in drug-related proceeds. Thomas F. Murdock, IRS Criminal Investigation Special Agent in Charge, pointed out that money laundering and drug distribution often coexist due to their symbiotic relationship within criminal organizations.
Sanabria's international operation and subsequent arrest highlight the complex challenges that regulatory agencies face in the fight against criminal pharmaceutical practices. Despite regulation efforts, these organizations persistently find loopholes to exploit, often to the detriment of public health and safety.
U.S. Attorney Rachelle Aud Crowe praised the collaborative effort of law enforcement agencies, such as the DEA and IRS, in disrupting dangerous operations like Sanabria's. She stressed that the dismantling of such operations is essential to the protection of consumers from the illicit drug industry's harmful tendencies.
